. MerrimackPharma Axes 60 of Workforce Explores Strategic Alternatives Halts MM121 Development httpow.lyh7zp30mxZkoÂpic.twitter.com47UhnQlR6d

. @MerrimackPharma Axes 60% of Workforce, Explores Strategic Alternatives, Halts MM-121 Development: http://ow.ly/h7zp30mxZko pic.twitter.com/47UhnQlR6d

12:25 EST 11 Nov 2018 | Genetic Engineering News

. @MerrimackPharma Axes 60% of Workforce, Explores Strategic Alternatives, Halts MM-121 Development: http://ow.ly/h7zp30mxZko  pic.twitter.com/47UhnQlR6d

More From BioPortfolio on ". @MerrimackPharma Axes 60% of Workforce, Explores Strategic Alternatives, Halts MM-121 Development: http://ow.ly/h7zp30mxZko pic.twitter.com/47UhnQlR6d"